Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Gantanol
Synonyms :
sulfamethoxazole
Class :
Antibiotic, Sulphonamides
Brand Name :
Gantanol
Synonyms :
sulfamethoxazole
Class :
Antibiotic, Sulphonamides
Dosage Forms & StrengthsÂ
Tablet Â
500 mg  Â
Take a dose of 2 g orally once followed by 1 g two times a day
Take a dose of 2 g orally once followed by 1 g every 6 to 12 hours up to 3 to 7 days
Take a dose of 2 g orally once followed by 1 g every 6 to 12 hours up to three weeks
Take a dose of 2 g orally once followed by 1 g every 8 hours up to 7 to 10 days
Dosage Forms & StrengthsÂ
Tablet Â
500 mg
For 13 to 18 years old:
Start dose with 50 to 60 mg/kg orally, followed by 25 to 30 mg/kg two times a day
Refer to adult dosingÂ
aminobenzoate potassium exhibits pharmacodynamic antagonism, resulting in reduced effects of sulfamethoxazole
interaction may lead to bone marrow suppression, avoid interaction with sulfonamide antibiotics
neomycin/polymyxin B/gramicidin ophthalmicÂ
may increase the nephrotoxic effect of Polymyxin B
mecamylamine: they may increase the toxic effect of sulfonamides
may enhance the anticoagulant effect
may enhance the anticoagulant effect
may enhance the anticoagulant effect
may enhance the anticoagulant effect
may enhance the anticoagulant effect
It may enhance the serum concentration when combined with CYP3A4 Substrates
When halometasone is used together with sulfamethoxazole, this leads to elevated risk or seriousness of hyperglycemia
may increase the hypotensive effect of blood pressure lowering agents
may increase the hypotensive effect of blood pressure lowering agents
may increase the hypotensive effect of blood pressure lowering agents
may increase the hypotensive effect of blood pressure lowering agents
may increase the hypotensive effect of blood pressure lowering agents
sulfamethoxazole: it may increase the risk or severity of QTc prolongation agents
sulfamethoxazole: it may increase the risk or severity of QTc prolongation agents
sulfamethoxazole: it may increase the risk or severity of QTc prolongation agents
sulfamethoxazole: it may increase the risk or severity of QTc prolongation agents
sulfamethoxazole: it may increase the risk or severity of QTc prolongation agents
sulfamethoxazole: it may decrease the excretion rate of benserazide
sulfamethoxazole: it may decrease the excretion rate of deferiprone
may diminish the therapeutic effect of drug
may diminish the therapeutic effect of drug
may diminish the therapeutic effect of drug
methylprednisolone hemisuccinateÂ
When methylprednisolone hemisuccinate is aided with sulfamethoxazole, this leads to elevated hyperglycemia risk
May enhance the therapeutic concentration of Zidovudine
May enhance the therapeutic concentration of Tenofovir alafenamide
May enhance the therapeutic concentration of tipranavir
dexketoprofen may enhance the risk of adverse effects of Sulfonamides
may increase the adverse effect of sulfonamides
may increase the hypoglycemic effect of sulfonylureas
ajmaline: they may increase the toxic effect of sulfonamides
It has the potential to increase the adverse/harmful effects of sulfonamides
may have an increased risk of hypoglycemia when combined with sulfamethoxazole
benazepril: it may increase the risk of hyperkalemia with sulfamethoxazole
bendamustine: it may increase the risk of myelosuppression with sulfamethoxazole
benorilate: it may increase the risk of hyperkalemia can be increased when sulfamethoxazole
benoxaprofen: it may increase the risk of hyperkalemia with sulfamethoxazole
cabergoline: it may increase the serum concentration of sulfamethoxazole
cabozantinib: it may decrease the metabolism of sulfamethoxazole
canagliflozin: it may increase the hypoglycemic activities of sulfamethoxazole
cannabidiol: it may decrease the metabolism of sulfamethoxazole
daunorubicin: it may increase the risk of myelosuppression with sulfamethoxazole
decitabine: it may increase the risk of myelosuppression with sulfamethoxazole
delafloxacin: it may increase the therapeutic efficacy of sulfamethoxazole
eletriptan: it may decrease the metabolism of sulfamethoxazole
elexacaftor: it may decrease the metabolism of sulfamethoxazole
eliglustat: it may decrease the metabolism of sulfamethoxazole
empagliflozin: it may increase the hypoglycemic activities of sulfamethoxazole
when both drugs are combined, there may be a decreased therapeutic efficacy of sulfamethoxazole  
when both drugs are combined, there may be an increased risk or severity of QTC prolongation  
Actions and SpectrumÂ
sulfamethoxazole inhibits the enzyme dihydropteroate synthase, which is essential for the synthesis of folic acid in bacteria. Folic acid is required to produce DNA, RNA, and proteins. Â
sulfamethoxazole prevents the growth and reproduction of the bacteria.
Frequency not defined Â
NauseaÂ
Vomiting Â
Skin rashÂ
Allergic reactionÂ
Black Box WarningÂ
The black box warning highlights the potential for severe and life-threatening hematologic effects, such as agranulocytosis, aplastic anemia, and other blood disorders.  Â
It also focuses on the risk of severe skin reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis. The black box warning includes information about potential liver toxicity. Sulfamethoxazole may cause liver problems, including hepatitis and jaundice.Â
Contraindication/Caution:Â
Contraindication:Â
Caution:Â
Pregnancy consideration:Â
Pregnancy category: BÂ
Lactation: Excretion into human milk is unknown Â
Pregnancy Categories:        Â
Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester.Â
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women. Â
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.Â
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.Â
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.Â
Category N: There is no data available for the drug under this category.Â
Pharmacology Â
Due to its structural similarity to para-aminobenzoic acid (PABA), an endogenous substrate, sulfamethoxazole is a sulfonamide that prevents bacteria from synthesizing dihydrofolic acid. Â
Unlike Animalia, which needs external supplies of folic acid, most bacteria obtain their folic acid needs by synthesizing it from PABA.Â
PharmacodynamicsÂ
The disruption of folic acid synthesis impairs bacterial growth and reproduction, rendering the bacteria unable to multiply and causing them to eventually die off or be eliminated by the immune system.Â
PharmacokineticsÂ
Absorption  Â
sulfamethoxazole is well absorbed from the gastrointestinal track.  Â
DistributionÂ
sulfamethoxazole is distributed throughout the body.Â
MetabolismÂ
sulfamethoxazole undergoes minimal metabolism in the body. Â
Elimination and excretionÂ
sulfamethoxazole is excreted in the urine.Â
AdministrationÂ
sulfamethoxazole is available in tablet form for oral intake.
Patient information leafletÂ
Generic Name: sulfamethoxazoleÂ
Why do we use sulfamethoxazole?Â
sulfamethoxazole is used to treat respiratory tract infections, such as bronchitis and pneumonia.Â
sulfamethoxazole is used to treat skin and soft tissue infections, including cellulitis, abscesses, and wound infection. Â
sulfamethoxazole used as a treatment and prophylactic therapy for toxoplasmosis, a parasitic infection. Â
sulfamethoxazole is often used to treat nocardiosis.Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
